Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

Pediatric Blood and Cancer

Volumn 50, Issue 5, 2008, Pages 970-975

  Choi, L Mi Rim ^a   Rood, Brian ^a,b   Kamani, Naynesh ^a,b   La Fond, Deborah ^a   Packer, Roger J ^a   Santi, Maria Rita ^a   MacDonald, Tobey J ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Childhood; CNS tumors; High dose chemotherapy; Metronomic chemotherapy

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; ISOTRETINOIN; METHOTREXATE; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG MEGADOSE; EPENDYMOMA; FEMALE; GLIOMA; HUMAN; MALE; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; METASTASIS; MORBIDITY; NEUROECTODERM TUMOR; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEASIBILITY STUDIES; GANGLIOGLIOMA; HUMANS; INFANT; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEUROECTODERMAL TUMORS, PRIMITIVE; OLIGODENDROGLIOMA; QUALITY OF LIFE; RETROSPECTIVE STUDIES; THIOTEPA; TREATMENT OUTCOME; VINCRISTINE;

EID: 41849122758     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21381     Document Type: Article

References (53)

1. Dufour C, Grill J, Lellouch-Tubiana A, et al. High-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006;42:2939-2945.
2. Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001;19:1288-1296.
3. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005;23:7621-7631.
4. Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: Results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006;24:1554-1560.
5. Thorarinsdottir HK, Rood B, Kamani N, et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007;48:278-284.
6. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725-1731.
7. Marec-Berard P, Jouvet A, Thiesse P, et al. Supratentorial embryonal tumors in children under 5 years of age: An SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol 2002;38:83-90.
8. Gardner SL. Application of stem cell transplant for brain tumors. Pediatr Transplant 2004;8:28-32.
9. Finlay JL. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors: A reappraisal. Pediatr Transplant 1999;3:87-95.
10. Wolff JE, Finlay JL. High-dose chemotherapy in childhood brain tumors. Onkologie 2004;27:239-245.
11. Dunkel IJ, Finlay JL. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit Rev Oncol Hematol 2002;41:197-204.
12. Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-221.
13. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
14. Drevs J, Laus C, Medinger M, et al. Antiangiogenesis: Current clinical data and future perspectives. Onkologie 2002;25:520-527.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
16. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
17. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220:545-554.
18. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
19. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-2735.
20. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-728.
21. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study. Onkologie 2006;29:308-313.
22. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105: R15-24.
23. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.
24. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 1996;27:149-155.
25. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14:1922-1927.
26. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001;54:31-38.
27. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.
28. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
29. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer 2007;96:6-10.
30. Gilbertson RJ. Brain tumors provide new clues to the source of cancer stem cells: Does oncology recapitulate ontogeny? Cell Cycle 2006;5:135-137.
31. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005;8:323-335.
32. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
33. Children's Oncology Group Protocol AEWS02P1. A pilot study of low-dose antiangiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors.
34. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002;49:117-120.
35. Children's Oncology Group Protocol ADVL0414. A phase I study of Temozolomide, Oral Irinotecan and Vincristine for children with refractory solid tumors.
36. Children's Oncology Group Protocol ACNS 0332. Efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients. A groupwise phase III study.
37. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 1999;17: 3720-3728.
38. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-7051.
39. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
40. Stempak D, Gammon J, Klein J, et al. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002;72:490-497.
41. Defer GL, Adle-Biassette H, Ricolfi F, et al. All-trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol 1997;34:169-177.
42. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003;9:1033-1038.
43. Puduvalli VK, Saito Y, Xu R, et al. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 1999;5:2230-2235.
44. Matthay KK, Villabianca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
45. Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005;61:1454-1459.
46. Jaeckle KA, Hess KR, Yung WK, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol 2003;21:2305-2311.
47. Sandri A, Massimino M, Mastrodicasa L, et al. Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol 2005;27:486-490.
48. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/ progressive sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-324.
49. Gajjar A, Mulhern RK, Heideman RL, et al. Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin Oncol 1994;12:1212-1216.
50. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: A report from the Childrens Cancer Group. J Clin Oncol 1994;12:1607-1615.
51. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005;23:1491-1499.
52. Zacharoulis S, Levy A, Chi SN, et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007;49: 34-40.
53. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-698.